Trial · NCT02972294
HiFIT Study : Hip Fracture: Iron and Tranexamic Acid
NCT02972294, Phase 3, Terminated, University Hospital, Angers
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. HiFIT Study : Hip Fracture: Iron and Tranexamic Acid. Trials, record NCT02972294. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02972294
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- HiFIT Study : Hip Fracture: Iron and Tranexamic Acid
- NCT number
- NCT02972294
- Status
- Terminated
- Phases
- Phase 3
- Enrollment
- 419 participants, actual
- Lead sponsor
- University Hospital, Angers
- Conditions
- Hip Fractures Pathologic, Anemia
- Interventions
- Iron Isomaltoside 1000, Tranexamic Acid, Placebos iron isomaltoside 1000, Placebos tranexamic acid
- First posted
- 2016-11-23
- Last updated
- 2022-08-02
Source ClinicalTrials.gov
Registered outcomes19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Proportion of patients who received a blood transfusion during their hospital stay following surgery | From the day of surgery until hospital discharge (or until day 30 if patient is still hospitalized). | Proportion of patients who received a blood transfusion during their hospital stay following surgery |
| Secondary | Proportion of patients who received a blood transfusion after surgery | From the day of surgery until Day 3, Day 7 and Day 30 post surgery. | Proportion of patients who received a blood transfusion during the month following surgery (including fresh frozen plasma and platelets) |
| Secondary | Number of packed red blood cell units transfused per patient, as well as number of fresh frozen plasma and platelets units | Till postoperative Day3, first week posteratively,and till hospital discharge (or one month if patients still hospitalised) | Number of packed red blood cell units transfused per patient, as well as number of fresh frozen plasma and platelets units |
| Secondary | Hemoglobin concentration | At inclusion and on days 3, 7 (or hospital discharge if it happens first) and 30. | Hemoglobin concentration |
| Secondary | Proportion of patients with anemia (hemoglobin <12 g/dL in women and <13 g/dL in men) | At inclusion and on days 3, 7, hospital discharge (if it happens before Day 30) and 30. | Proportion of patients with anemia (hemoglobin \<12 g/dL in women and \<13 g/dL in men) |
| Secondary | Reticulocytes count | On days 3, 7 (or hospital discharge if it happens first) and 30 post surgery | Reticulocytes count |
| Secondary | Perioperative blood loss (estimated according to a formula based on hematocrit variation). | During surgery | Perioperative blood loss (estimated according to a formula based on hematocrit variation): (HtD0 - HtD3)\*TBV + number of RPBC transfused unit x 200 ml. Ht = Haematocrit, TBV = total blood volume (70 mL/kg in men and 65 mL/kg in women) |
| Secondary | Post operative Iron deficiency rate | On Day 7 (or hospital discharge if it happens first) and Day 30. | Proportion of patients with Iron deficiency (defined as a ferritin \< 100 ng/ml or \< 300 ng/ml together with transferrin saturation \<20%), measurement of ferritin and transferrin saturation |
| Secondary | Number of hospitalization days | On Day 30 and Day 90 following surgery. | Number of hospitalization days |
| Secondary | Proportion of patients at home | On Day 30 and Day 90. | Proportion of patients returned at home (or at their previous place of living) |
1 to 10 of 19Source ClinicalTrials.gov
See all 19 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02972294
GET https://conductscience.org/api/trials/v1/NCT02972294/registered